Solid Biosciences report on DMD gene therapy trial

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Solid Biosciences today announced preliminary findings from its IGNITE-DMD trial, which has so far tested SGT-001 in three boys. Muscle biopsies taken after three months showed low levels of micro-dystrophin protein. Although this is disappointing news, it’s important to remember that IGNITE-DMD is a dose-escalation study, and these three boys received the lowest planned dose. These results confirm that a higher dose of SGT-001 will need to be tested in future patients.

For further information, please read Solid’s community letter and press release.

If you have any questions about this news story or any other Duchenne research, please contact the MDUK Research Line on 020 7803 4813 or email

Keep in touch